Polaroid

Polaroid Therapeutics is a Swiss biotechnology company focused on developing a new class of antimicrobial peptides to combat multi-drug resistant infections. Leveraging its proprietary technology platform, the company designs synthetic peptides that mimic the natural immune system's ability to disrupt bacterial membranes and biofilms. Their lead programs target chronic wound infections and surgical site complications, aiming to provide effective alternatives to traditional antibiotics. The company's approach seeks to minimize the development of bacterial resistance while maintaining high efficacy and safety profiles. By integrating advanced material science with biotechnology, Polaroid Therapeutics is positioning itself as a leader in the next generation of infection control. The company is currently progressing its lead candidates through the pre-clinical pipeline toward human clinical trials.